A passionate team and partners
How to Navigate the Website
What people say about us
Prilenia Phase 3 Trial with Pridopidine – Why is it Different?
– September 13th, 2022
For all those who have been following Huntington’s disease research for some time, Pridopidine is an “old acquaintance”.
To date, several studies have been conducted with this drug, looking closely to its effect on dopamine. Although they have helped us to confirm the safety and good tolerability of pridopidine, none of these trials has been completely successful.
UniQure: the Highs and Lows of AMT-130
– September 9th, 2022
UniQure is a company with an expertise in gene therapy that has long been involved in the search for HD treatment options. Their preclinical studies in animal models showed that AMT-130, the gene therapy product candidate for HD, reduced the mutant huntingtin protein and was associated with a decrease in the progression of Huntington’s disease signs.
PIVOT-HD, PTC Therapeutics Phase 2 Trial to Lower Huntingtin
– September 8th, 2022
PTC Therapeutics is a US biopharmaceutical company specialized in the development of gene therapies for rare diseases. The team at PTC Therapeutics has screened more than 300,000 molecules in the search for an effective therapeutical approach to HD, one that can lower huntingtin, can be administered orally and can have an impact inside and outside of the brain.
Online Conversation (in Spanish) with French Adventurer Dimitri Poffé
– August 18th, 2022
Last June, our Project Coordinator in Russia, Zaynab Umakhanova, had the opportunity to interview Dimitri Poffé and learn everything about his project “Explore for Huntington”.
Because of this project, which got him cycling all over Latin America for the last 6 months, Dimitri has also learned to speak Spanish.
The Moving Forward “Let Us Talk” work was among the top scoring presentations at the European Conference on Rare Diseases & Orphan Products
– July 18th, 2022
In a busy month of work dissemination, Filipa Júlio, from the Moving Forward team, attended the 11th European Conference on Rare Diseases & Orphan Products at the end of June.
This online event was joined by over 800 people from the rare diseases’ community across Europe and it was thought to be the perfect platform to showcase the Moving Forward work about “Let Us Talk: A Communication Skills Training Course for Healthcare Professionals working with Huntington’s Disease”
Participate in our Forum!
– May 6th, 2022
- This is your moment to speak and be heard.
- This is your moment to learn from others and benefit from their experience.
- This is the moment to use your voice!